Robert Koski - Dec 8, 2022 Form 4 Insider Report for ORAGENICS INC (OGEN)

Role
Director
Signature
/s/ Mark A. Catchur, as Attorney-in-Fact for Robert C. Koski
Stock symbol
OGEN
Transactions as of
Dec 8, 2022
Transactions value $
-$2,607
Form type
4
Date filed
12/9/2022, 03:14 PM
Previous filing
Dec 1, 2022
Next filing
Dec 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OGEN Common Stock Sale -$2.61K -13K -0.95% $0.20 1.36M Dec 8, 2022 See footnote F1, F2
holding OGEN Common Stock 53.1K Dec 8, 2022 See footnote F3
holding OGEN Common Stock 213K Dec 8, 2022 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The prices reported in Column 4 are weighted average prices on the Transaction Date indicated. The shares were sold in multiple transactions ranging from $0.1901 to $0.2000 on the Transaction Date. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F2 Represents shares owned by the Koski Family Limited Partnership ("KFLP"). The reporting person serves as one of the general partners of the KFLP and disclaims beneficial ownership of the securities reflected as held by the KFLP except to the extent of the reporting person's pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner for purposes of Section 16 or any other purpose.
F3 Shares owned by trusts of which Mr. Robert C. Koski is sole trustee. Such trusts are as follows: the Robert Clayton Koski Trust for the benefit of Anthony James Hunter (10,760 shares); the Robert Clayton Koski Trust for the benefit of Hunter Buchanan Koski (10,760 shares); the Robert Clayton Koski Trust for the benefit of Clayton Ward Bennett (10,000 shares); the Robert Clayton Koski Trust for the benefit of Robert Edward Koski (10,760 shares); and the Robert Clayton Koski Trust for the benefit of Elyse Margaux Koski (10,806 shares). Mr. Koski disclaims beneficial ownership of the shares held by the trusts except to the extent of any pecuniary interest.
F4 Shares owned directly by Robert C. Koski, a director of the Company.